Extended Research Article
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
Nigel Fleeman
,
Rachel Houten
,
Sarah Nevitt
,
James Mahon
,
Sophie Beale
,
Angela Boland
et al.
-
Journal:
Health Technology Assessment Volume: 28, Issue: 49
-
Published:
29 August 2024